UNSPSC 51182203: Oxytocin

This classification denotes a pituitary hormone with the molecular formula C43H66N12O12S2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 1JQS135EYN, chemically known as vasopressin, 3-l-isoleucine-8-l-leucine- but more generally known as oxytocin, which bears U.S. National Institutes of Health Compound Identifier 5771. The European Medicines Agency schedules Oxytocin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09580MIG.

UNSPSC 51182203 Oxytocin is a Commodity code addressing pharmaceutical supply through cooperative purchasing vehicles. State and local governments procure this drug as part of broader pharmaceutical procurement programs, typically bundled with generic multi-source drugs and over-the-counter products distributed across state agencies, local health departments, and supporting healthcare facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) exemplifies current procurement activity: the alliance solicits manufacturers and distributors to supply pharmaceuticals including oxytocin under master agreements that participating states and localities then leverage for direct purchases. Issuing bodies using this code span state health departments, state procurement offices administering cooperative agreements, and participating local government health systems. MMCAP itself, administered through the Minnesota Department of Administration's Office of State Procurement, serves as the contracting entity on behalf of multiple states including Oregon and other alliance members, making cooperative purchasing vehicles the dominant mechanism for this commodity class.

The most recent activity centers on the upper Midwest and Pacific Northwest, with MMCAP's multi-state membership providing geographic breadth across participating jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 on January 20, 2026, requesting proposals from manufacturers to supply generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), with proposals due March 26, 2026. Evaluation emphasizes price competitiveness (75 percent), fixed pricing (10 percent), and compliance with administrative and data formatting requirements (15 percent combined). Vendors must maintain contractual relationships with at least two of the three authorized wholesalers, certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and carry commercial general liability insurance of $5,000,000. The resulting contracts become effective July 1, 2026, for a two-year term with optional MMCAP extensions, representing the primary procurement pathway for pharmaceutical commodities including oxytocin at the state and local level.